Organon
Commercializes women's health medicines, biosimilars, and established brands.
$13.76
After-hours close0.00 (0.00%)
At close$13.76(0.00%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.91 | — | — |
| Jul 2026 | $0.91 | $0.41 | −54.9% |
| Apr 2026 | $0.83 | $0.71 | −14.5% |
| Feb 2026 | $0.73 | $0.63 | −13.7% |
| Nov 2025 | $0.93 | $1.01 | +8.6% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | $0.91 | — | — | $1.58B | — | — |
| Jul 31, 2026 | $0.91 | $0.41 | −54.9% | $1.57B | $1.56B | −0.8% |
| Apr 30, 2026 | $0.83 | $0.71 | −14.5% | $1.49B | $1.46B | −1.9% |
| Feb 12, 2026 | $0.73 | $0.63 | −13.7% | $1.53B | $1.51B | −1.8% |
| Nov 10, 2025 | $0.93 | $1.01 | +8.6% | $1.52B | $1.60B | +5.3% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 5, 2025 | ||||||
| May 1, 2025 | ||||||
| Feb 13, 2025 | ||||||
| Oct 31, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 15, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 16, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 17, 2022 | ||||||
| Nov 11, 2021 | ||||||
| Aug 12, 2021 | ||||||
| Jun 21, 2021 | ||||||
| Mar 17, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||